CoChat
Sign Up
Cited by 67Multiple Sclerosis Research StudiesHealth Systems, Economic Evaluations, Quality of LifePsoriasis: Treatment and Pathogenesis

Influence of Interferon beta treatment on quality of life in multiple sclerosis patients

Open access
Simone, Isabella Laura, Ceccarelli, Antonia, Tortorella, Carla, Bellacosa, Alessandra, Pellegrini, Fabio, Plasmati, Immacolata, De Caro, Maria Fara, Lopez, Mariangela +2 more·2006·Health and Quality of Life Outcomes
DOI 10.1186/1477-7525-4-96PMC PMC1716163
Open this paper in CoChat — free accountOpen PDF

Abstract

BACKGROUND: Interferon-beta (IFN-beta) shows beneficial effect on the course of multiple sclerosis (MS), nevertheless its route and frequency of administration and side effects might impact negatively the quality of life (QoL) of MS patients. The objective of this study was to evaluate the influence of IFN-beta on QoL in MS patients. METHODS: Seventy-seven disease modifying treatment (DMT) free and 41 IFN-beta treated MS patients were evaluated. QoL, assessed by MSQoL-54, was related to IFN-beta treatment and to clinical and demographic parameters at baseline and after two years. Multivariate hierarchical linear model for repeated measurements was used. RESULTS: Treated patients showed a younger age, a lower disease duration and a higher relapse rate in the two years preceding study entry. At inclusion time treated and untreated patients did not differ in relapse rate, expanded disability status scale (EDSS), fatigue, depression, physical and mental QoL. IFN-beta did not influence QoL at inclusion time, but when QoL was evaluated after two years, treatment negatively affected mental QoL. Depression and fatigue negatively influenced physical and mental QoL both at baseline and after two years. EDSS correlated with a poor physical QoL only at baseline. CONCLUSION: IFN-beta had a negative impact on QoL over the time in MS patients, influencing mainly mental QoL. The impairment of QoL in MS was strongly associated with increasing fatigue and depression, whereas clinical disability had a minor unfavourable role.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/1477-7525-4-96

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 29

  1. Nortvedt MW Riise T Myhr KM Nyland HI Quality of life in multiple sclerosis: measuring the disease effects more broadly Neurology 1999 53 1098 1103 10496273
  2. The Canadian Burden of Illness Study Group Burden of illness of multiple sclerosis. II. Quality of life Can J Neurol Sci 1998 25 31 38 9532278
  3. Nortvedt MW Riise T The use of quality of life measures in multiple sclerosis research Mult Scler 2003 9 63 72 12617271 10.1191/1352458503ms871oa · DOI
  4. Kurtzke JF Rating neurological impairment in multiple sclerosis: An expanded disability status scale (EDSS) Neurology 1983 33 1444 1452 6685237
  5. Shawaryn MA Schiaffino KM LaRocca NG Johnston MV Determinants of health-related quality of life in multiple sclerosis: the role of illness intrusiveness Mult Scler 2002 8 310 318 12166502 10.1191/1352458502ms808oa · DOI
  6. Amato MP Ponziani G Rossi F Liedl CL Stefanile C Rossi L Quality of life in multiple sclerosis: the impact of depression, fatigue and disability Mult Scler 2001 7 340 344 11724451 10.1191/135245801681138059 · DOI
  7. Patti F Capocardo M Palermo F Ciancio MR Lopes R Restivo D Reggio A Health-related quality of life and depression in an Italian sample of multiple sclerosis patients J Neurol Sci 2003 211 55 62 12767498
  8. Janssen ACJW van Doorn PA de Boer JB Kalkers NF van der Mechè FCA Passchier J Anxiety and depression influence the relation between disability status and quality of life in multiple sclerosis Mult Scler 2003 9 397 403 12926846 10.1191/1352458503ms930oa · DOI
  9. Lobentanz IS Asenbaum S Vass K Sauter C Klosch G Kollegger H Ristoferitsch W Zeitlhofer J Factors influencing quality of life in multiple sclerosis patients, depressive mood, fatigue and sleep quality Acta Neurol Scand 2004 110 6 13 15180801 10.1111/j.1600-0404.2004.00257.x · DOI · Paper page
  10. Mitchell AJ Benito-León J Moralez-Gonzales JM Rivera-Navarro J Quality of life and its assessment in multiple sclerosis: integrating physical and psychological components of wellbeing Lancet Neurol 2005 4 556 566 16109362 10.1016/S1474-4422(05)70166-6 · DOI
  11. Rice GP Oger J Duquette P Francis GS Belanger M Laplante S Grenier JF Treatment with interferon beta-1b improves quality of life in multiple sclerosis Can J Neurol Sci 1999 26 276 282 10563212
  12. Arnoulds JHA Kilestein J Pfennings L Jelles B Uitdehaag BMJ Polman CH Quality of life during the first 6 months of interferon-β treatment in patients with MS Mult Scler 2000 6 338 342 11064444 10.1191/135245800678827932 · DOI
  13. Nortvedt MW Riise T Myhr KM Nyland HI Hanestad BR Type I interferons and the quality of life of multiple sclerosis patients. Results from a clinical trial on interferon alfa-2a Mult Scler 1999 5 317 322 10516774 10.1191/135245899678846339 · DOI
  14. McDonald WI Compston A Edan G Goodkin D Hartung HP Lublin FD McFarland HF Paty DW Polman CH Reingold SC Sandberg-Wollheim M Sibley W Thompson A van den Noort S Weinshenker BY Wolinsky JS Recommended diagnostic criteria for multiple sclerosis: guidelines from International Panel on the diagnosis of multiple sclerosis Ann Neurol 2001 50 21 127 10.1002/ana.1032 11456302 · DOI · Paper page
  15. Solari A Filippini G Mendozzi L Ghezzi A Cifani S Barbieri E Baldini S Salmeggi A La Mantia L Farinotti M Caputo D Mosconi P Validation of italian multiple sclerosis quality of life 54 questionnaire J Neurol Neurosurg Psychiatry 1999 67 158 162 10406981 PMC1736469
  16. Ware JE Sherbourne CD A 36-item short-form health survey (SF-36): I. Conceptual framework and item selection Med Care 1992 30 473 483 1593914 10.1097/00005650-199206000-00002 · DOI · Paper page
  17. Krupp LB La Rocca NG Muir-Nash J Steinberg AD The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus Arch Neurol 1989 46 1121 1124 2803071
  18. Beck AT Ward CH Mendelson M Mock JE Erbaugh JK An inventory for measuring depression Arch Gen Psychiatry 1961 4 561 571 13688369
  19. Singer JD Willett JB Applied Longitudinal Data Analysis: Modeling Change and Event Occurrence 2003 New York: Oxford University Press
  20. Diggle PJ Liang KY Zeger SL Analysis of Longitudinal Data 1994 Oxford: Oxford University Press
  21. Gottberg K Garduf A Fredrikson S Interferon-beta treatment for patients with multiple sclerosis: the patients' perceptions of the side-effects Mult Scler 2000 6 349 354 11064446 10.1191/135245800678827978 · DOI
  22. Freeman JA Thompson AJ Fitzpatrick R Hutchinson M Miltenburger C Beckmann K Dahlke F Kappos L Polman C Pozzilli C European Study Group Interferon-beta1b in Secondary Progressive MS Interferon-β 1b in the treatment of secondary progressive MS. Impact on quality of life Neurology 2001 57 1870 1875 11723278
  23. Cohen JA Cutter GR Fischer JS Goodman AD Heidenreich FR Kooijmans MF Sandrock AW Rudick RA Simon JH Simonian NA Tsao EC Whitaker JN IMPACT Investigators Benefit of interferon β-1a on MSFC progression in secondary progressive MS Neurology 2002 59 679 687 12221157
  24. Isaksson AK Ahlström G Gunnarsson LG Quality of life and impairment in patients with multiple sclerosis J Neurol Neurosurg Psychiatry 2005 76 64 69 15607997 10.1136/jnnp.2003.029660 PMC1739311 · DOI
  25. Pittock SJ Mayr WT McClelland RL Jorgensen NW Weigand SD Noseworthy JH Rodriguez M Quality of life is favorable for must patients with multiple sclerosis Arch Neurol 2000 61 679 686 15148144 10.1001/archneur.61.5.679 · DOI
  26. Solari A Ferrari G Radice D A longitudinal survey of self-assessed health trends in a community cohort of people with multiple sclerosis and their significant others J Neurol Sci 2006 243 13 20 16380136 10.1016/j.jns.2005.11.005 · DOI
  27. Vermersch P de Seze J Delisse B Lemaire S Stojkovic T Quality of life in multiple sclerosis: influence of interferon-beta1 a (Avonex) treatmen Mult Scler 2002 8 377 381 12356203 10.1191/1352458502ms826oa · DOI · Paper page
  28. Janardhan V Baskshi R Quality of life in patients with multiple sclerosis: The impact of fatigue and depression J Neurol Sci 2002 205 51 58 12409184 10.1016/S0022-510X(02)00312-X · DOI · Paper page
  29. Fisk JD Brown MG Sketris IS Metz LM Murray TJ Stadnyk KJ A comparison of health utility measures for the evaluation of multiple sclerosis treatments J Neurol Neurosurg Psychiatry 2005 76 58 63 15607996 10.1136/jnnp.2003.017897 PMC1739294 · DOI

Cited by

Sorted by citations

Authors
Simone, I. L., Ceccarelli, A., Tortorella, C., Bellacosa, A., Pellegrini, F., Plasmati, I., De Caro, M. F., Lopez, M., Girolamo, F., & Livrea, P.
Affiliations
  • University of Bari Aldo Moro (IT)
  • Mario Negri Institute for Pharmacological Research (IT)
Corresponding author
Simone, Isabella Laura
ORCID
Venue
Health and Quality of Life Outcomes
Publisher
Springer Science and Business Media LLC
Published
2006-12
Volume
4
Issue
1
Pages
96-96
ISSN
1477-7525 (ISSN-L)
DOI
10.1186/1477-7525-4-96
PMC
PMC1716163
OpenAlex
W2134558833
Cited by
67
References
3
Citations by year
2026: 1 · 2024: 3 · 2023: 2 · 2022: 2 · 2021: 3 · 2020: 1 · 2019: 3 · 2018: 1 · 2017: 1 · 2016: 3 · 2015: 4 · 2014: 3 · 2013: 2 · 2012: 4
FWCI
4.22
Type
journal article
Language
en
Open access
Licence
Locations
  • Health and Quality of Life Outcomes (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) (submittedVersion)
Funders
Ministero dell’Istruzione, dell’Università e della Ricerca (PRIN 2004)
Topics
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Multiple Sclerosis Research Studies
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
  • Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
Keywords
interferon-beta, multiple sclerosis, quality of life, mental health, fatigue, depression, Expanded Disability Status Scale, disability progression, relapse rate, MSQOL-54
MeSH terms
Adult, Attitude to Health, Depression, Fatigue, Female, Humans, Immunologic Factors, Italy, Male, Middle Aged, Multiple Sclerosis, Pain, Quality of Life, Time Factors, Multivariate Analysis, Interferon-beta, Episode of Care, Outcome Assessment, Health Care, Sickness Impact Profile

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review